首页> 外文期刊>International Journal of General Medicine >Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome
【24h】

Expression and Clinical Prognostic Value of Platelet NLRP3 in Acute Coronary Syndrome

机译:血小板NLRP3在急性冠状动脉综合征中的表达及临床预后价值

获取原文
       

摘要

Purpose: Little is known about the relationship between the level of platelet NOD-like receptor protein 3 (NLRP3) and the severity of acute coronary syndrome (ACS) or the prognostic value of platelet NLRP3 for percutaneous coronary intervention (PCI). Methods: Platelets collected from 25 healthy subjects, 23 patients with stable angina pectoris (SAP), and 72 patients with ACS were analyzed by Western blotting and real-time fluorescence quantitative PCR (qPCR). A total of 152 patients with ACS who had undergone PCI were included in this study to evaluate the prognostic value of platelet NLRP3 . Results: The levels of platelet NLRP3 in both the healthy and SAP groups were clearly lower than in the ACS group ( P 0.001). According to the Pearson correlation analysis, the expression of platelet NLRP3 was closely related to the mean platelet volume (MPV), left ventricular ejection fraction (LVEF), the Gensini score, and the Global Registry of Acute Coronary Events (GRACE) score (all P 0.001). Multivariate logistic regression analysis identified NLRP3 as an independent risk factor for adverse cardiovascular events (ACEs) after PCI ( P =0.004). The proportion of patients with high NLPR3 expression (the NLRP3 -high group) remaining free of adverse events for 3 years was remarkably lower than that in patients with low NLPR3 expression (the NLRP3 -low group; P =0.024). The NLRP3 -high group had a significantly higher proportion of patients with interleukin-1β–expressing (20.4%± 6.1%) platelets than the NLRP3 -low group (10.7%± 3.5%, P 0.001). Moreover, the NLRP3 -high group exhibited higher platelet activity, as indicated by increased PAC-1 binding and CD62P expression, compared with the NLRP3 -low group ( P 0.001). Conclusion: These results indicated that platelet NLRP3 was a novel potential prognostic factor for patients with ACS that underwent PCI.
机译:目的:关于血小板点状受体蛋白3(NLRP3)水平与急性冠状动脉综合征(ACS)的严重程度的关系,或血小板NLRP3用于经皮冠状动脉介入(PCI)之间的关系。方法:通过蛋白质印迹和实时荧光定量PCR(QPCR)分析从25个健康受试者收集的血小板,23例稳定的心绞痛患者(SAP)和72例ACS患者分析。本研究中包含共152例经历PCI的ACS患者,以评估血小板NLRP3的预后值。结果:健康和SAP组血小板NLRP3的水平明显低于ACS组(P <0.001)。根据Pearson相关分析,血小板NLRP3的表达与平均血小板体积(MPV),左心室喷射分数(LVEF),Gensini评分和急性冠状动脉事件(Grace)得分的全球注册表(全部p <0.001)。多变量逻辑回归分析将NLRP3确定为PCI后不利心血管事件(ACE)的独立危险因素(P = 0.004)。高NLPR3表达(NLRP3 -High组)的比例仍然没有3年的不良事件,比NLPR3表达的患者(NLRP3 -LOW组; P = 0.024)显着低。 NLRP3 -High族的血小板与NLRP3 -LOW组(10.7%±3.5%,P <0.001)具有明显更高的白细胞介素-1β-1β-1β-表达(20.4%±6.1%)血小板比例。此外,与NLRP3 -LOW基团相比,NLRP3 -High组表现出更高的血小板活性,如增加的PAC-1结合和CD62P表达式所示(P <0.001)。结论:这些结果表明,血小板NLRP3是接受PCI的ACS患者的新潜在预后因素。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号